SUSPECT ADVERSE REACTION REPORT

PA-Tolmar-TLM-2025-01201

I. REACTION INFORMATION

1. PATIENT INITIALS (first, last)	1a. COUNTRY	2. DATE OF BIRTH			2a. AGE Years	3. SEX	4-6 REACTION ONSET		
		Day	Month	Year			Day	Month	Year
P-R	PANAMA	18	Jan	1937	88	Male	31	Mar	2023

7+13 DESCRIBE REACTION(S) (including relevant tests/lab data)

1) didn't feel like doing anything (Depressed mood (10012374), Depressed mood (10012374))
(31/Mar/2023 -) - Not Recovered/Not Resolved/Ongoing
2) A lot of weakness (Weakness (10047862), Asthenia (10003549))
(31/Mar/2023 -) - Not Recovered/Not Resolved/Ongoing
3) knee discomfort (Arthralgia (10003239), Arthralgia (10003239))
(31/Mar/2023 -) - Not Recovered/Not Resolved/Ongoing
4) Cessation of therapy by the healthcare professional (Therapy cessation by healthcare provider (10072906), Therapy cessation (10065154))
Unknown

Cont..

8-12 CHECK ALL APPROPRIATE TO ADVERSE REACTION

- ☐ PATIENT DIED
- ☐ LIFE THREATENING
- ☐ INVOLVED OR PROLONGED INPATIENT HOSPITALIZATION
- ☐ RESULTS IN PERSISTENCE OR SIGNIFICANT DISABILITY/INCAPACITY
- ☐ CONGENITAL ANOMALY
- ☐ OTHER MEDICALLY IMPORTANT CONDITION

II. SUSPECT DRUG(S)INFORMATION

14. SUSPECT DRUG(S)(include generic name)

1) Eligard® (Leuprolide acetate, Leuprolide acetate) (Suspect) (Injection)(Unknown)(Unknown)

Cont..

20. DID EVENT ABATE AFTER STOPPING DRUG? ☐ YES ☐ NO ☑ NA

15. DAILY DOSE(S)	16. ROUTE(S) OF ADMINISTRATION
1) (45 milligram(s), 1 in 6 Month)	1) Subcutaneous
2) (45 milligram(s), 1 in 6 Month)	2) Subcutaneous

21. DID EVENT REAPPEAR AFTER REINTRODUCTION ☐ YES ☐ NO ☑ NA

(NA : Not Applicable)

17. INDICATION(S) FOR USE

1) Prostate cancer [10060862 - Prostate cancer]

18. THERAPY DATE(S) (from/to)	19. THERAPY DURATION
1) (31/Mar/2023 - UNK)	

III. CONCOMITANT DRUG(S) AND HISTORY

22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction)

1)Amlodipine(AMLODIPINE)

Cont..

23. OTHER RELEVANT HISTORY (e.g. diagnostics, allergies, pregnancy with last month of period, etc.)

1) PROSTATE CANCER (10060862, Prostate cancer) (Continuing: Yes)

Cont..

IV. MANUFACTURER INFORMATION

24a. NAME AND ADDRESS OF MANUFACTURER

Name : Tolmar, Inc
701 Centre Avenue
Fort Collins, CO, 80526, UNITED STATES OF AMERICA
Anjan.Chatterjee@tolmar.comand+1-9702124900

Study Information
Study Name: NA
EudraCT Number:
Protocol No.: NA
Center No.:
Subject Id :

24.REPORT NULLIFIED	24b. MFR CONTROL NO.
☐ YES ☐ NO	PA-Tolmar-TLM-2025-01201
24c. DATE RECEIVED BY MANUFACTURER: 19/Jun/2025	24d. REPORT SOURCE: ☑ STUDY ☐ LITERATURE ☐ HEALTH PROFESSIONAL
DATE OF THIS REPORT: 25/Jun/2025	25a. REPORT TYPE: ☐ INITIAL ☑ FOLLOWUP

= Continuation attached sheet(s)..

Continuation Sheet for CIOMS report

7+13 DESCRIBE REACTION(S) (including relevant tests/lab data) (Continuation...)

Event Description :

This study report from Panama was received by Adium via Patient Support Program (Reference number: PA-ADIUM-PA-0046-20250428) on 28-Apr-2025 from a consumer (non-healthcare professional) regarding an elderly, 88-year-old male patient who experienced non-serious events of ‘a lot of weakness' (asthenia), ‘didn't feel like doing anything' (depressed mood), ‘Cessation of therapy by the healthcare professional' (therapy cessation) during Eligard (leuprolide acetate) 45 mg therapy for Prostate cancer. The needle component of the constituent device was not identified in the report. The report was sent to Tolmar on 01-May-2025.

The patient's medical history was unknown and current condition included prostate cancer and hypertension.

Concomitant medication included amlodipine.

On 31-Mar-2023, the patient began receiving Eligard 45 mg, every 6 months, via subcutaneous route, for Prostate cancer (Lot numbers and Expiration dates were not provided).

On an unknown date, the patient received Eligard 45 mg, every 6 months, via subcutaneous route, for prostate cancer (Lot numbers and Expiration dates were not provided). He experienced extreme weakness and a lack of desire to do anything that he continued to experience the symptoms but assumed that those aforementioned symptoms were normal because the testosterone hormone kept him agile and energetic. It was his hormone the body needs and gave him motivation, and if it was reduced due to a lack of testosterone.

On 21-Apr-2025, the patient had a testosterone test.

On 22-Apr-2025, the patient went to see the doctor to validate the results, which were 0.05 ng/ml. The doctor told the patient these were the levels he should have and scheduled his next appointment (for 20 or 25-May-2025), to have his testosterone levels checked again and determine whether or not to administer Eligard. The patient mentioned that his testosterone levels were being monitored with blood tests to validate his levels, and based on the results, he was given Eligard.

Corrective treatment was not reported.

Relevant test results included:
On 21-Apr-2025: Testosterone: 0.05 ng/ml (Ref. range not provided)
On an unknown date: Testosterone: Testosterone levels continued to be low (Ref. range not provided)

Action taken with Eligard in response to events was unknown. De-challenge and re-challenge were not applicable.

The outcomes of asthenia, depressed mood were not resolved, and therapy cessation was unknown.

The reporter did not assess the seriousness of asthenia, depressed mood and therapy cessation.

The reporter did not provide the causality of asthenia, depressed mood and therapy cessation in relationship to Eligard and Eligard unspecified device.

No follow-up queries were raised.

Listedness
Therapy cessation >Eligard® >unlisted as per CCDS Eligard®> 7-Nov-2024
Therapy cessation> Eligard® >unlisted as per Canadian Monograph Eligard®> 2-Apr-2025
Therapy cessation> Eligard®>unlisted as per USPI Eligard®>Feb-2025
Therapy cessation> Eligard® Unspecified Device>unlisted as per USPI Eligard®>Feb-2025

Asthenia>Eligard® >listed as per CCDS Eligard®> 7-Nov-2024
Asthenia> Eligard® >listed as per Canadian Monograph Eligard®> 2-Apr-2025
Asthenia> Eligard®>listed as per USPI Eligard®>Feb-2025
Asthenia> Eligard® Unspecified Device> listed as per USPI Eligard®>Feb-2025

Depressed mood >Eligard® >listed as per CCDS Eligard®> 7-Nov-2024
Depressed mood > Eligard® >listed as per Canadian Monograph Eligard®> 2-Apr-2025
Depressed mood > Eligard®>listed as per USPI Eligard®>Feb-2025
Depressed mood > Eligard® Unspecified Device> listed as per USPI Eligard®>Feb-2025

On 19-Jun-2025, follow-up information from Panama was received by Adium via Patient Support Program (reference number: PA-ADIUM-PA-0046-20250428 (1)) from a consumer (non-healthcare professional) regarding an elderly 88-year-old male patient. The report was sent to Tolmar on 20-Jun-2025. New information included: a new non-serious event 'knee discomfort' (arthralgia) was added. Corrective treatment added. Date details of events were updated. Causality of events added.

The patient medical history and current condition included prostate cancer and hypertension.

Continuation Sheet for CIOMS report

On 31-Mar-2023, patient experienced knee discomfort with extreme weakness and a lack of desire to do anything.

Corrective treatment for arthralgia included Tylenol.

Action taken with Eligard in response to the event was unknown. De-challenge and re-challenge were not applicable.

The outcome of arthralgia is Not recovered / unresolved / ongoing.

The reporter did not assess the seriousness of arthralgia.

The reporter assessed the causality of arthralgia, asthenia, depressed mood in relationship to Eligard and Eligard Unspecified Device as related.
Arthralgia>Eligard® >listed as per CCDS Eligard®> 7-Nov-2024
Arthralgia> Eligard® >listed as per Canadian Monograph Eligard®> 2-Apr-2025
Arthralgia> Eligard®>listed as per USPI Eligard®>Feb-2025
Arthralgia> Eligard® Unspecified Device> listed as per USPI Eligard®>Feb-2025

Company Remarks (Sender's Comments) :

Evaluator comment (Tolmar): This is regarding an elderly, 88-year-old male patient who experienced asthenia (a lot of weakness), depressed mood (didn't feel like doing anything) and therapy cessation (Cessation of therapy by the healthcare professional) during Eligard (leuprolide acetate) 45 mg therapy for Prostate cancer. Tolmar assessed the reported events as non-serious since they did not meet the ICH seriousness criteria. The causality of events asthenia and depressed mood were assessed as related to suspect drug Eligard(not related to device) considering the known safety profile of the drug, elderly age and prostate cancer could be confounders for the events. The causality of the event therapy cessation was assessed as not related to suspect Eligard(drug and device) as it was a decision made by health care professional in response to the underlying condition and testosterone values.
The causality for the reported event arthralgia is assessed as related with Eligard (drug) based on implied temporality and known safety profile of the drug. Patient's elderly age and underlying malignancy are risk factors. Event arthralgia is not related with device.

Additional Information (Continuation...)

Lab Result :

Test Name	Test Date	Test Result	Normal Value
TESTOSTERONE	21/Apr/2025	0.05 nanogram per millliter	
TESTOSTERONE			

Test Result (Code) / Result Unstructured Data (free text) :

2) Test Name: TESTOSTERONE

Result Unstructured Data (free text) : Testosterone levels continued to be low
Test Date:

14.SUSPECT DRUG(S) (Continuation...)

Product-Reaction Level

1) Drug : Eligard® (Leuprolide acetate)
Active Substance : 1) Leuprolide acetate
Drug Characterization : Suspect
Form of Admin : 1) Injection
2) Injection
Lot Number : 1) Unknown
2) Unknown
Daily Dose : (45 milligram(s), 1 in 6 Month)
(45 milligram(s), 1 in 6 Month)
Route of Admin : 1) Subcutaneous
2) Subcutaneous
Indications : 1) Prostate cancer [10060862 - Prostate cancer]
Therapy Dates : 1) From : 31/Mar/2023 To :Unknown
Action(s) Taken With Drug : Unknown

Causality

Continuation Sheet for CIOMS report

1) didn't feel like doing anything (Depressed mood - 10012374, Depressed mood - 10012374)
Causality as per reporter : Related
Causality as per Mfr : Related
DeChallenge : Not applicable
ReChallenge : Not Applicable
2) A lot of weakness (Weakness - 10047862, Asthenia - 10003549)
Causality as per reporter : Related
Causality as per Mfr : Related
DeChallenge : Not applicable
ReChallenge : Not Applicable
3) knee discomfort (Arthralgia - 10003239, Arthralgia - 10003239)
Causality as per reporter : Related
Causality as per Mfr : Related
DeChallenge : Not applicable
ReChallenge : Not Applicable
4) Cessation of therapy by the healthcare professional (Therapy cessation by healthcare provider - 10072906, Therapy cessation - 10065154)
Causality as per reporter : Not Reported
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

Labeling :

1) didn't feel like doing anything
CORE Labeled
2) A lot of weakness
CORE Labeled
3) knee discomfort
CORE Labeled
4) Cessation of therapy by the healthcare professional
CORE UnLabeled

2) Drug : Eligard® Unspecified Device (Leuprolide acetate)
Active Substance : 1) Leuprolide acetate
Drug Characterization : Suspect
Form of Admin : 1) Injection
Lot Number : 1) Unknown
Indications : 1) Prostate cancer [10060862 - Prostate cancer]
Action(s) Taken With Drug : Not applicable

Causality

1) didn't feel like doing anything (Depressed mood - 10012374, Depressed mood - 10012374)
Causality as per reporter : Not Reported
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable
2) A lot of weakness (Weakness - 10047862, Asthenia - 10003549)
Causality as per reporter : Not Reported
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable
3) knee discomfort (Arthralgia - 10003239, Arthralgia - 10003239)
Causality as per reporter : Not Reported
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable
4) Cessation of therapy by the healthcare professional (Therapy cessation by healthcare provider - 10072906, Therapy cessation - 10065154)
Causality as per reporter : Not Reported
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

Labeling :

1) didn't feel like doing anything
CORE
2) A lot of weakness
CORE
3) knee discomfort

Continuation Sheet for CIOMS report

CORE
4) Cessation of therapy by the healthcare professional
CORE

15. DAILY DOSE(S) (Continuation...)

Dosage Text :

Drug 1 :Eligard®

1) ELIGARD 45 MG x 1 LIO x 1 JER

22.CONCOMITANT DRUG(S) (Continuation...)

1). Drug	:	Amlodipine
Active Substance	:	1) AMLODIPINE
Form Strength	:	
Daily Dose	:	1) (1 in 1 Day)
Indications	:	1) hypertension [10020772 - Hypertension]

23. OTHER RELEVANT HISTORY (Continuation...)

2) HYPERTENSION (HIGH BLOOD PRESSURE) (10020772 , Hypertension) (Continuing : YES)